Document:

<PAGE>

                                                                   Exhibit 10.11

                         MASTER CLINICAL TRIAL AGREEMENT

THIS MASTER CLINICAL TRIAL AGREEMENT (the "Agreement") is effective January 9,
2006 (the "Effective Date") between Cleveland Clinic Florida, a Florida
not-for-profit corporation ("CCF"), and Ivivi Technologies, Inc., a New Jersey
corporation ("Sponsor"), having the respective addresses as set forth below.
Each of CCF and Sponsor may be referred to individually herein as a "Party," and
jointly as the "Parties."

WHEREAS, CCF possesses certain expertise in the field of clinical and related
research and evaluation of such research; and

WHEREAS, Sponsor is interested in engaging CCF in order to obtain the benefit of
such expertise with respect to certain research and development projects being
conducted by Sponsor into the clinical development, safety and efficacy of
various medical devices being developed by Sponsor;

Therefore, in consideration of the premises and undertakings set forth. herein,
CCF and Sponsor agree as follows:

1.   DEFINITIONS.

     1.1  "CFR" means the United States Code of Federal Regulations.

     1.2  "CONSENT FORM" shall have the meaning ascribed in Section 7.

     1.3  "DATA" shall have the meaning ascribed in Section 14.4.

     1.4  "FDA" means the United States Food and Drug Administration.

     1.5  "FD&C ACT" means the United States Federal Food, Drug and Cosmetic
          Act, as may be amended from time to time. /

     1.6  "GCP" means the Guidelines for Good Clinical Practices promulgated by
          the International Conference on Harmonisation of Technical
          Requirements for Registration of Pharmaceuticals for Human Use.

     1.7  "IRS" means a CCF Institutional Review Board.

     1.8  "INVESTIGATOR" means the principal investigator for a Study, as
          specified in the applicable Work Order.

     1.9  "MATERIALS" means all substances, compounds, devices and/or materials
          provided to CCF by or on behalf of Sponsor for use in the performance
          of a Study.

<PAGE>

     1.10 "PRODUCT" means a proprietary investigational device(s) of Sponsor
          that is(are) the subject of a Study.

     1.11 "PROPRIETARY INFORMATION" means all confidential information and
          Materials implied or expressly identified as such in Sponsor's sole
          discretion, including, but not limited to know-how, trade secrets,
          technical data, technical specifications, testing methods, technology,
          expertise, any information implied or expressly designated as
          "Proprietary Information" under this Agreement and associated Work
          Orders, or any other information, whether or not patentable or
          copyrightable, that is disclosed or provided by Sponsor to CCF in
          connection with (a) this Agreement, (b) the terms of this Agreement,
          (c) any associated Work Order, or (d) the terms of any associated Work
          Order..

     1.12 "PROTOCOL" means the protocol for the conduct of a Study, as set forth
          in the relevant Work Order.

     1.13 "Study" means one or more clinical research studies requested by
          Sponsor and agreed to be performed by CCF as set forth in the relevant
          Work Order, which may be referred to collectively as the "Studies."

     1.14 "Work Order" shall have the meaning ascribed in Section 3.1(a).

2.   SCOPE OF THE AGREEMENT.

The Parties intend for this Agreement to allow them to contract for multiple
Studies through the issuance of Work Orders without having to re-negotiate the
basic terms and conditions contained herein.

3.   WORK ORDERS.

     3.1  The specific details of each Study under this Agreement shall be
          separately negotiated by the Parties and specified in writing, on
          terms and in a form acceptable to the Parties (each such writing, a
          "Work Order"). Each Work Order will include the Protocol, time line
          and payment schedule for such Study. A sample Work Order is attached
          hereto as Exhibit A.

     3.2  CCF shall conduct each Study covered by each executed Work Order in
          accordance with the terms and conditions of such Work Order. Each
          executed Work Order shall be deemed to be a part of this Agreement;
          provided that, to the extent any terms or provisions of a Work Order
          conflict with the terms and provisions of this Agreement, the terms
          and provisions of this Agreement shall control, except to the limited
          extent that the applicable Work Order expressly and specifically
          states an intent to supersede this Agreement on a specific matter.

4.   INVESTIGATORS' QUALIFICATIONS

     4.1  Each Work Order shall identify the Investigator for the Study that is
          the subject of such Work Order (including, to the extent requested by
          Sponsor, detailed

                                        2

<PAGE>

          curriculum vitae, certificates of training and description of proposed
          responsibilities and time commitment).

     4.2  With respect to each Study, the applicable Investigator shall make the
          following representations to Sponsor as part of each Work Order:

          (a) Such Investigator has no financial interests and/or arrangements
     with Sponsor that will require disclosure to FDA in accordance with 21 CFR
     Part 54;

          (b) Such Investigator has not been "debarred" by the FDA under the
     provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. Section
     335a (a) and (b), nor have debarment proceedings been commenced against him
     or her;

          (c) Such Investigator is aware of and agrees to be bound by the terms
     of this Agreement (including without limitation Articles 5, 14 and 15
     hereof) and of the Work Order covering such Study.

     4.3  With respect to each Study, CCF and/or the applicable Investigator
          shall also supply the following documents:

          (a) A signed investigator statement (Form FDA-1572) and curriculum
     vitae for all individuals listed therein, and

          (b) If such Investigator has been involved in an investigation or
     other research that has been terminated for cause, an explanation of the
     circumstances that led to such termination shall be attached.

5.   IRB APPROVAL

For each Study to be conducted hereunder, Sponsor shall provide to the
applicable Investigator for submission to the IRB, adequate information (i.e.
investigator's brochure, the Protocol, and sample informed consent form) for
review and approval to begin such Study. If any modification of such informed
consent form is required by the IRB, a copy of the form as modified shall be
promptly provided to Sponsor for its approval. Any withdrawal of IRS approval
shall be immediately reported to Sponsor.

6.   CONDUCT OF STUDIES, GENERALLY

     6.1  CCF shall commence each Study as soon as possible following receipt of
          IRB written approval, or as otherwise agreed upon in writing with
          Sponsor, and shall follow any conditions of approval imposed by the
          IRB.

     6.2  CCF and the applicable Investigator shall conduct each Study in
          accordance with all applicable federal and state laws and regulations
          for protecting the rights, safety and welfare of human subjects and
          for the control of investigational drugs and devices, including 21 CFR
          Parts 50, 56 and 312, and all recognized medical and ethical standards
          for the conduct of clinical investigations, including GCP.

                                        3

<PAGE>

     6.3  Except in the case of a medical emergency or otherwise necessary for
          patient safety, neither CCF nor any Investigator shall not make any
          changes in, nor deviate from, the applicable Protocol without Sponsor'
          prior written approval.

     6.4  Sponsor or its designee will provide clinical monitoring for each
          Study. CCF and the applicable Investigator shall cooperate with
          Sponsor and/or its designee in the performance of its duties as
          clinical monitor.

     6.5  Any substitutions or replacements of an Investigator during the course
          of a Study must first be approved in writing by Sponsor. In the event
          that the Investigator for a Study becomes unable or unwilling to
          continue to perform his or her responsibilities under such Study, CCF
          shall use its best efforts to provide a replacement acceptable to
          Sponsor as promptly as possible. If CCF in unable to replace such
          Investigator to Sponsor' reasonable satisfaction, Sponsor shall have
          the right to terminate such Study upon written notice to CCF, as set
          forth in Section 6.6 below.

     6.6  Sponsor reserves the right to terminate any Study at any time with or
          without cause upon written notice to the CCF and the applicable
          Investigator. Upon receipt of initial notice of termination of a Study
          from Sponsor, CCF and the applicable Investigator shall cease the
          clinical investigation of the applicable Product and the enrollment of
          further subjects into such Study. CCF and the applicable Investigator
          shall continue to collect Data and prepare case report forms for
          subjects who received such Product prior to receipt of the termination
          notice as directed in writing by Sponsor. Upon termination, CCF will
          be reimbursed by Sponsor for (a) all fees incurred in its conduct of
          such Study through the effective date of such termination, and for any
          further Data and case report form processing as described above, in
          accordance with the payment schedule set forth in the applicable Work
          Order adjusted pro rata for actual work completed to Sponsor's
          satisfaction by CCF through the effective date of such termination,
          and (b) any reasonable, non-cancelable costs approved by Sponsor
          resulting from the termination following Sponsor' receipt of an
          itemized invoice detailing such costs.

7.   INFORMED CONSENT

For each Study to be conduced hereunder, and in accordance with 21 CFR Part 50
and 312.60, CCF shall inform all subjects of such Study or their legal
representatives that the applicable Product is being used for clinical
investigation, and shall obtain from these subjects or their legal
representatives a signed written informed consent form which has been approved
by the IRB and Sponsor (a "Consent Form"). Each subject shall be provided a
photocopy of his or her signed Consent Form, the original of which shall be
placed in the respective subject's investigational file.

                                        4

<PAGE>

8.   SUPERVISING USE

In accordance with 21 CFR Part 312.61, CCF shall permit the Product that is the
subject of a Study to be used only by subjects under the applicable
Investigator's supervision, or under the supervision of the associates listed on
the applicable Form FDA-1572. The CCF shall not supply the Product to any person
other than those authorized under this Agreement. No investigative procedures
other than those set forth in the corresponding Protocol shall be undertaken
with such Product on the enrolled subjects or otherwise without the prior
written approval of Sponsor (and the IRB when necessary). CCF will not supply
such Product, nor permit such Product to be supplied, to any third party
(including, without limitation, any other investigator except the
above-referenced associates) or laboratory or any clinic for use in humans or
for in vitro or in vivo laboratory research, or any other use, without the prior
written approval of Sponsor.

9.   RECORDS

     9.1  CCF shall maintain the following accurate, complete and current
          records with respect to each Study, and shall make such records
          available to Sponsor and its authorized representatives promptly upon
          request

          (a)  Any and all correspondence with Sponsor, the IRB and the FDA.

          (b) In accordance with 21 CFR 312.62, records of receipt, use or
     disposition of the Product that is the subject of such Study including
     without limitation:

               (i) The date of receipt, type, quantity, lot number and other
          identifying marks of such Product;

               (ii) The names of all persons who received, used or disposed of
          each unit of such Product;

               (iii) An explanation of the reasons why any Product was returned
          to Sponsor (excluding the routine return of such Product upon
          completion or other termination of such Study).

          (c) In accordance with 21 CFR 312.62, source records of each subject's
     case history and exposure to such Product. The records shall:

               (i) Include copies of signed Consent Forms;

               (ii) Except with respect to Consent Forms, be transcribed onto
          Sponsor-supplied case report forms and be completed at times indicated
          by Sponsor;

               (iii) Include all observations, and other data and records
          pertinent to such Study, and all records concerning adverse events.

          (d) The applicable Protocol, and any amendments thereto, with
     documents showing the dates of and reasons for each deviation from such
     Protocol.

                                        5

<PAGE>

     9.2  CCF shall review, sign and date the case report forms for each subject
          enrolled in a Study. Source documents must be available for copy and
          review as needed by Sponsor to audit or correct study case report
          forms or to respond to the FDA. CCF shall make such source documents
          and records available for inspection and copying at pre-Study and
          routine clinical monitoring visits. CCF and its staff shall cooperate
          with Sponsor during monitoring visits or for the resolution of
          questions regarding records or clinical data generated throughout the
          performance of this Agreement.

     9.3  The parties recognize that the sharing of clinical data with Sponsor
          in the performance, audit or monitoring of a Study may involve
          disclosure of individually identifiable health information, as that
          term is defined under the privacy rules of the Health Insurance
          Portability and Accountability Act of 1996. The parties each agree to
          treat all individually identifiable health information disclosed as
          part of a Study as confidential and in accordance with the patient's
          written authorization and all applicable federal, state or local laws
          and regulations governing confidentiality and privacy of individually
          identifiable health information.

10.  REPORTS

     10.1 CCF shall prepare and submit to Sponsor or its designee the following
          complete, accurate and timely reports with respect to each Study:

          (a) Case Report Forms: CCF shall submit completed case report forms as
     required in the applicable Protocol or as otherwise requested by Sponsor.
     In the event subject follow-up is not possible for any reason, CCF shall
     document this fact and the circumstances thereof on a case report form and
     promptly submit such form.

          (b) Adverse Events; Any serious adverse events that occur during such
     Study shall be reported by CCF to Sponsor, and to the IRB if required by
     federal regulations (including without limitation 21 CFR 312), as soon as
     possible, but in no event later than twenty-four (24) hours following
     receipt of such information.

          (c) Withdrawal of IRB Approval: CCF shall report to Sponsor the IRB's
     withdrawal of approval of the CCF's or applicable Investigator's
     participation in a Study immediately following receipt of such notice from
     the IRB.

          (d) Deviations from the Protocol: CCF shall promptly notify Sponsor of
     any deviation from the Protocol, as permitted under Section 5.4.

          (e) Informed Consent CCF shall promptly notify Sponsor and the IRB of
     any failure to obtain informed consent from a subject in accordance with
     Article 7 prior to such subject's participation in a Study, within five (5)
     working days after discovery of such failure occurs.

                                        6

<PAGE>

     10.2 CCF shall provide to Sponsor (i) periodic written progress reports for
          each Study, and (ii) a final written report for such Study, in each
          case as described in the applicable Work Order.

11.  COMPENSATION

     11.1 CCF will be compensated by Sponsor for its conduct of each Study in
          accordance with the payment terms and fee schedule set forth in the
          applicable Work Order.

     11.2 Unless otherwise set forth in the applicable Work Order, CCF's
          payments shall be made payable to the following name and address:

                            Cleveland Clinic Florida
                                 P.O. Box 918631
                             Orlando, FL 32891-8631

Each payment voucher should reflect the Sponsor's name, Protocol Number, and
name of the applicable Investigator.

          A. Sponsor shall report any payments made to CCF under this Agreement,
          and shall withhold from such payments any required taxes for
          remittance to the applicable authority, solely to the extent required
          by applicable federal, state or local tax laws or regulations. CCF's
          Federal Tax Identification Number is 65-0003177. CCF shall be solely
          responsible for the filing of all forms and the payment of all taxes
          and withholdings in connection with amounts paid to it by the Sponsor.
          CCF shall indemnify the Sponsor and hold the Sponsor harmless with
          respect to the payment of all taxes and withholdings required to be
          paid by CCF in accordance with applicable federal, state or local tax
          laws or regulations.

12.  REGULATORY ISSUES; INSPECTIONS.

     12.1 Each of Sponsor and CCF shall be responsible for obtaining and
          maintaining, at its respective expense, all permits, licenses,
          approvals, authorizations and the like required for its respective
          performance under this Agreement.

     12.2 If any governmental or regulatory authority or any entity representing
          such an authority (each, a "Regulatory Authority") requests access to
          CCF's records, facilities and/or personnel, or conducts an unannounced
          inspection, in each case relating to a Study, then CCF shall promptly
          notify the contact set forth in the Work Order covering such Study by
          telephone. Sponsor shall have the right to be present at any audit or
          inspection by a Regulatory Authority that relates to a Study.

     12.3 Sponsor has the right to examine and audit the work performed by CCF
          pursuant to any Study at the facilities where the work is conducted,
          upon reasonable

                                        7

<PAGE>

          advance notice during regular business hours, to determine that CCF is
          conducting the Study in accordance with the applicable Work Order and
          applicable regulatory requirements, and that CCF is providing adequate
          facilities and staffing to the satisfaction of Sponsor.

13.  DISPOSING OF CLINICAL SUPPLIES

In accordance with 21 CFR 312.59, upon the earlier of completion or termination
of each Study or at Sponsor' request, CCF shall return to Sponsor any remaining
Product (including investigational devices, if any) and other Materials from
such Study, or, if so instructed by Sponsor, destroy any such remaining Product
in accordance with the instructions provided by Sponsor and consistent with
applicable local, state and federal guidelines and shall supply Sponsor with a
certificate of such destruction.

14.  CONFIDENTIALITY/INTELLECTUAL PROPERTY

     14.1 CCF hereby agrees:

          (a) not to use any Proprietary Information except for the purpose of
     conducting the applicable Study or as otherwise expressly authorized in
     writing by Sponsor, and

          (b) not to disclose or transfer Proprietary Information to any person
     or entity, other than to those employees or agents (including without
     limitation Investigators) who reasonably require same for the purpose
     hereof and who are bound by like written obligations to protect such
     Proprietary Information, without the express written permission of Sponsor.

          (c) The obligations of this provision shall remain in effect for three
     (3) years following the disclosure of such Proprietary Information.

     14.2 The obligations set forth in Section 14.1 shall not apply to any
          Proprietary Information that:

          (a) CCF can demonstrate by written records was known to CCF prior to
     its disclosure hereunder; or

          (b) is now or later becomes publicly available other than by breach of
     this Agreement; or

          (c) is lawfully disclosed to the recipient on a non-confidential basis
     by a third party who is not obligated to Sponsor or any other party to
     retain such Proprietary Information in confidence.

     14.3 Nothing in this Agreement shall prevent CCF from disclosing
          Proprietary Information that is duly required to be disclosed by order
          of a court, government agency or the like having competent
          jurisdiction, provided that CCF shall promptly notify Sponsor to
          permit Sponsor to seek a protective order or

                                        8

<PAGE>

          injunctive relief to protect the confidentiality of the Proprietary
          Information. CCF shall disclose only such portion of the Proprietary
          Information as is required to be so disclosed

     14.4 The case report forms, progress reports, and any other reports
          prepared as part of the Study, as well as any other tangible
          manifestation of the results of the Study, shall be the sole and
          exclusive property of Sponsor. Nothing in this Article 14, however,
          shall prevent the CCF from maintaining copies of such materials to use
          for (i) regulatory compliance purposes and evidencing compliance with
          this Agreement; (ii) publishing scientific articles on the Study, as
          contemplated by Article 15 below; or (iii) internal research,
          education and patient care purposes, subject to the surviving
          obligations of Section 14.1.

     14.5 The furnishing of Proprietary Information under this Agreement shall
          not constitute any grant, option or license to the CCF under any
          patent or other rights now or hereafter held by Sponsor. This
          Agreement shall not be deemed or construed to convey or transfer to
          CCF any rights with respect to any Product, except as insofar as
          necessary to permit CCF and the applicable Investigator to conduct the
          Study.

     14.6 INVENTIONS.

                               SPONSOR INVENTIONS

          (a) Notification. If the conduct of the Study results in a "Sponsor
     Invention" defined as an invention or discovery, whether patentable or not,
     that (1) relates directly to the Sponsor Product, including any that
     contemplate either a new use or new formulation of the Sponsor Product, (2)
     was made possible through use of Sponsor Confidential Information, (3) was
     made possible through use of Sponsor funding under the Study Protocol, this
     Agreement, and any subsequent amendments thereto, or (4) results from any
     investigation of the Sponsor Product conducted under the Study Protocol,
     this Agreement, and any subsequent amendments thereto, CCF will promptly
     inform Sponsor.

          (b) Assignment to Sponsor. CCF will assign all interest in any such
     Sponsor Invention to Sponsor, free of any obligation or consideration
     beyond that provided for in this Agreement.

          (c) Assistance. CCF will provide reasonable assistance to Sponsor in
     filing and prosecuting any patent applications relating to such Sponsor
     Invention, at Sponsor's expense.

                                 CCF INVENTIONS

          (d) Notification. If the conduct of Study results in any invention or
     discovery, whether patentable or not, that does not meet the definition of
     a Sponsor Invention, CCF will promptly inform Sponsor. Such an invention
     will be termed a 'CCF Invention" and ownership will be determined in
     accordance with US patent law. Sponsor will accept notification of a CCF
     Invention in confidence and, for a period of one year or until CCF

                                        9

<PAGE>

     files a patent application directed to the CCF Invention, whichever occurs
     first, will not disclose it to any third party without written consent from
     CCF unless required by law (including FDA regulations).

          (e) Option to a License. CCF grants Sponsor an option to a worldwide
     royalty-bearing license for each CCF Invention. The license sought can be
     exclusive or non-exclusive, at Sponsor's option. Any such license will
     include reasonable terms, to be negotiated in good faith.

          (f) Option Term. Sponsor's option will remain in effect for a period
     of 12 months from the date CCF discloses the CCF Invention to Sponsor in
     writing.

     14.7 Joint Technology. Subject to Section 14 all expenses incurred to
          obtain and maintain patents on Joint Technology defined as an
          invention or discovery whether patentable or not, that is mutually
          agreed upon by Sponsor and CCF to be owned by Sponsor and CCF, shall
          be divided equally between the parties and title to all such patents
          shall be jointly held. Subject to Section 14.8, each party shall have
          the right to license, with rights to sublicense, jointly owned patents
          to third parties, with the consent of, the other party.

     14.8 License to Joint Technology. Sponsor shall have the Option and Right
          to exclusively license CCF's rights in Joint Technology in a Field of
          Use.

     14.9 Patent Filing and Expenses.

          (a) Control Over Filings. CCF shall control the preparation and
     prosecution of all patent applications and the maintenance of all patents
     related to CCF Inventions. Sponsor shall control the preparation and
     prosecution of all patent applications and the maintenance of all patents
     related to Sponsor Inventions and Joint Technology.

          (b) Costs and Expenses. CCF may file patent applications covering CCF
     Technology at its own discretion and expense, or at the request of Sponsor
     at Sponsor's expense provided an agreement to license CCF technology to
     Sponsor can be reached pursuant to Section 14.6(d) - 14.6(f).

15.  PUBLICATION OF RESULTS

     15.1 Sponsor recognizes and accepts the importance of communicating medical
          study and scientific data and the necessity of conveying such
          information in a timely manner, and, therefore, encourages their
          publication in reputable scientific journals and at seminars or
          conferences.

          Sponsor further recognizes and accepts that under CCF's mission as an
          academic medical center, CCF and its investigators must have a
          meaningful right to publish research results without Sponsor's
          approval or editorial control, regardless of the Study's outcome. CCF
          shall submit to Sponsor for its review a copy of any proposed
          manuscript, paper, or poster resulting from the research thirty (30)
          days prior to the estimated date of submission for publication. If any
          proprietary Information is identified by Sponsor in good faith but
          according

                                       10

<PAGE>

          to Sponsor's sole discretion, as being in the manuscript, paper, or
          poster, CCF warrants that the proprietary information will be deleted
          at Sponsor's request. Additionally, if Sponsor reasonably determines
          that the proposed publication contains patentable subject matter which
          requires protection, Sponsor may require the delay of publication for
          a period of time not to exceed sixty (60) days for the purpose of
          filing patent applications. If no written response is received from
          Sponsor within the applicable review period, it may be conclusively
          presumed that publication may proceed without delay.

     15.2 Any proposed publications which are to make public any findings, data,
          or results of the Study shall be submitted to Sponsor for Sponsor's
          review and comment at least thirty (30) days prior to submission of a
          manuscript for publication, or at least seven (7) days prior to
          submission for an abstract. If any proprietary Information is
          identified by Sponsor in good faith but according to Sponsor's sole
          discretion, as being in the proposed publication, CCF warrants that
          the proprietary information will be deleted at Sponsors request.
          Additionally, if Sponsor reasonably determines that the proposed
          publication contains patentable subject matters which requires
          protection, Sponsor may require the delay of publication for a period
          of time not to exceed sixty (60) days for the purpose of filing patent
          applications. If no written response is received from Sponsor within
          the applicable review period, it may be conclusively presumed that
          publication may proceed without delay.

     15.3 Notwithstanding the foregoing, if a particular Study is a part of a
          multi-center study, CCF agrees that the first publication of the
          results of such Study shall be made in conjunction with the
          presentation of a joint, multi-center publication by all appropriate
          sites. However, if such a multi-center publication is not submitted
          within twelve (12) months after conclusion, abandonment or termination
          of the Study, or after Sponsor confirms there will be no multi-center
          Study publication, CCF and/or the Principal Investigator may proceed
          to publish the Study results in accordance with the above procedure.
          CCF and/or the Principal Investigator may thereafter publish either
          their own results or the combined results of all participating sites
          in accordance with the procedures above.

     15.4 The above procedure does not apply to information on prematurely
          discontinued and other non-completed studies unless Sponsor has
          provided written consent for such use.

16.  REPRESENTATIONS AND WARRANTIES

     16.1 CCF hereby represents and warrants that:

          (a) It is under no obligation to any third party, and will not during
     the term of this Agreement agree to assume any obligation to any third
     party, that would conflict with, prohibit or otherwise interfere with its
     performance of its obligations under this Agreement;

                                       11

<PAGE>

          (b) it has no financial interests and/or arrangements with Sponsor
     that will require disclosure to FDA in accordance with 21 CFR Part 54;

          (c) it has not been debarred under 21 U.S.C. Section 335(a) or 335(b),
     and will not use the services of any persons debarred under 21 U.S.C.
     Section 335(a) or 335(b) in any capacity in connection with the performance
     of its obligations under this Agreement;

          (d) neither CCF nor any CCF official or employee has been convicted of
     a felony under Federal law for conduct relating to the development or
     approval, including the process for development or approval, of any drug,
     product, medical device, NDA, abbreviated NDA, PMA or IND; and

          (e) no CCF official or employee has been convicted of a felony under
     United States law for conduct otherwise relating to the regulation of any
     drug product or medical device under the FD&C Act.

     16.2 Sponsor hereby represents and warrants that:

          (a) It is under no obligation to any third party that would interfere
     with its performance of its obligations under this Agreement;

          (b) It has not been debarred, excluded, suspended or otherwise
     determined to be ineligible to participate in any federal health care
     reimbursement programs, including the medicare and medicaid programs.

17.  INDEMNIFICATION

Each party (the "Indemnifying Party") shall indemnify, defend, and hold harmless
the other party (the "Indemnified Party(degree)), its directors, shareholders,
students, employees, trustees, officers, affiliates, and agents from and against
any and all third-party claims, suits, actions, investigations, proceedings and
related costs and expenses, all damages, costs, penalties, and expenses,
including reasonable attorneys' fees, which may be sustained or incurred by the
Indemnified Party at any time that are primarily attributable to the negligence
or misconduct of the Indemnifying Party, including without limitation, breach of
this Agreement or violation of federal, state, or local statutes, laws, or
regulations. If either party wishes to make a claim for indemnity, such party
shall provide written notice thereof to the other party. The Indemnifying Party
and the Indemnified Party shall each have the right to select counsel of their
own choosing at their own expense to represent them in any action resulting from
a claim or suit for which indemnification is sought. The Indemnifying Party and
the Indemnified Party hereby agree to cooperate fully in the resolution of any
such claim or suit. The obligations created under this provision shall survive
the termination of this Agreement.

18.  SUBJECT INJURY

Sponsor shall not be required to provide reimbursement to CCF to the extent that
a Subject's injuries (1) are otherwise covered by the Subject's medical or
hospital insurance coverage or other third party payment, and (2) are not
primarily attributable to (i) a significant departure from the Study Protocol
without good cause, (ii) the gross negligence, willful misconduct, or medical

                                       12

<PAGE>

malpractice of the CCF, the Principal Investigator, or any of the CCF's
students, employees, trustees, officers, affiliates, or agents, (iii) the
failure of the affected Subject to follow specific instructions, or (iv) a lack
of effectiveness or therapeutic benefit of the Study Drug. Further, Sponsor
shall not be required to reimburse the CCF for any claims of temporary pain or
discomfort on the part of a Subject or for any treatment related to the natural
progression of a Subject's pre-existing condition.

19.  NOTICES

All notices, requests, consents and other communications under this Agreement
shall be in writing and shall be delivered by hand or mailed by first class,
certified or registered mail, return receipt requested, postage prepaid, as
follows (or to such other address as a Party hereto may notify the other in
writing):

In the case of Sponsor, addressed to:

Ivivi Technologies, Inc.
Attn: Chief Science Officer
224-S Pegasus Avenue
Northvale, NJ 07647

when of a clinical nature or otherwise related to the Study, directed to the
attention of:

Ivivi Technologies, Inc.
Attn: President
224-S Pegasus Avenue
Northvale, NJ 07647

In the case of CCF, addressed to:

when of a clinical nature or otherwise related to the Study, directed to the
attention of the Investigator of such Study.

20.  TERM AND TERMINATION

     20.1 This Agreement shall become effective as of the Effective Date, and
          shall remain in force until the third (3rd) anniversary of the
          Effective Date and may be extended by mutual written agreement of the
          parties, unless and until terminated as set forth in Section 6.6,
          Section 20.2, or by written agreement of the Parties. Upon such
          termination, all currently on-going Studies shall terminate with the
          effect set forth in Section 6.6.

     20.2 Either Party may terminate this Agreement if the other Party
          materially breaches this Agreement and such breaching Party fails to
          cure such breach within thirty (30) days from the receipt of written
          notice from the non-breaching Party of such material breach. However,
          Sponsor may at any time terminate this Agreement in accordance with
          Section 6.6.

                                       13

<PAGE>

     20.3 The following provisions shall survive termination of this Agreement:
          Sections 6.6, 9.3, and Articles 12, 14, 15, 17, and 18. Termination of
          this Agreement shall not relieve either Party of any liability which
          accrued hereunder prior to the effective date of such termination, nor
          preclude either Party from pursuing all rights and remedies it may
          have hereunder or at law or in equity with respect to any breach of
          this Agreement, nor prejudice either Party's right to obtain
          performance of any obligation. The remedies provided under this
          Agreement are cumulative, and are not exclusive of other remedies
          available to a Party in law or equity.

     20.4 Upon receipt of notice of termination, Principal Investigator agrees
          to promptly terminate conduct of the Study to the extent medically
          permissible for any patients. In the event of termination hereunder,
          Sponsor, CCF and Principal Investigator will promptly enter into good
          faith discussions concerning an amount appropriate for those services
          performed in accordance with the Protocol for actual work performed
          through the date of termination, with any unexpected funds previously
          paid by Sponsor to CCF being refunded to Sponsor.

21.  MISCELLANEOUS PROVISIONS

     21.1 CCF shall not assign, subcontract or otherwise transfer any of its
          rights or obligations hereunder, or any part hereof, without the prior
          written consent of Sponsor. Any such assignment or transfer made
          without Sponsor' prior written consent shall be null and void.

     21.2 CCF shall, at all times, be an independent contractor, not an agent of
          Sponsor, and shall have no actual, apparent or implied authority to
          act or make representations for, or on behalf of, or to bind or commit
          Sponsor in any manner or to any obligation whatsoever.

     21.3 Except as may be required by law, each Party will obtain prior written
          permission from the other Party before using the name, symbols and/or
          marks of such other Party, or such Party's employees or agents, in any
          form of publicity.

     21.4 Paragraph and section headings are included for convenience of
          reference only and form no part of the agreement between the parties.

     21.5 Any delay in enforcing a Party's rights under this Agreement or any
          waiver as to a particular default or other matter shall not constitute
          a waiver of such Party's rights to the future enforcement of its
          rights under this Agreement, excepting only as to an express written
          and signed waiver as to a particular matter for a particular period of
          time.

     21.6 If any provision of this Agreement is or becomes or is deemed to be
          invalid, illegal, or unenforceable in any jurisdiction, then such
          provision will be deemed amended to conform to applicable laws of such
          jurisdiction so as to be valid and enforceable. If such provision
          cannot be so amended without materially altering the intention of the
          Parties, then it will be stricken. The validity, legality and

                                       14

<PAGE>

          enforceability of such provision will not in any way be affected or
          impaired thereby in any other jurisdiction, and the remainder of this
          Agreement will remain in full force and effect.

     21.7 This Agreement, and any Work Orders executed in connection herewith,
          set forth the complete, final and exclusive agreement between the
          Parties with respect to the subject matter hereof, and all of the
          covenants, promises, agreements, warranties, representations,
          conditions and understandings between the Parties hereto with respect
          to such subject matter, and supersedes and terminates all prior
          agreements and understandings between the parties with respect to such
          subject matter. There are no covenants, promises, agreements,
          warranties, representations, conditions or understandings, either oral
          or written, between the Parties with respect to such subject matter
          other than as are set forth herein and therein. No subsequent
          alteration, amendment, change or addition to this Agreement shall be
          binding upon the Parties unless reduced to writing and signed by an
          authorized officer of each Party.

     21.8 By entering into this Agreement, the parties specifically intend to
          comply with all applicable laws, rules and regulations, including (i)
          the federal anti-kickback statute (42 U.S.C. 1320a-7(b)) and the
          related safe harbor regulations; and (ii) the Limitation on Certain
          Physician Referrals, also referred to as the "Stark Law" (42 U.S.C.
          1395nn). Accordingly, no part of any consideration paid hereunder is a
          prohibited payment for the recommending or arranging for the referral
          of business or the ordering of items or services; nor are the payments
          intended to induce illegal referrals of business. In the event that
          any part of this Agreement is determined to violate federal, state, or
          local laws, rules, or regulations, the parties agree to negotiate in
          good faith revisions to the provision or provisions that are in
          violation. In the event the parties are unable to agree to new or
          modified terms as required to bring the entire Agreement into
          compliance, either party may terminate this Agreement on sixty (60)
          days written notice to the other party.

     21.9 This Agreement and any Work Orders executed in connection herewith
          shall be governed by and construed in accordance with the laws of the
          State of New Jersey irrespective of any conflicts of law principles.

          IN WITNESS THEREOF, the parties have executed this Agreement as of the
Effective Date.

SPONSOR                                 CLEVELAND CLINIC FLORIDA

By: /s/ Andre' DiMino                   By: /s/ Scott Campbell
    ---------------------------------       ------------------------------------
Print Name: Andre' DiMino               Print Name: Scott Campbell
            -------------------------               ----------------------------
Title: Chairman                         Title: Chief Financial Officer
       ------------------------------          ---------------------------------
Date:                                   Date:
      -------------------------------         ----------------------------------

                                       15

<PAGE>

                                    EXHIBIT A

                               FORM OF WORK ORDER

WORK ORDER # 001

This Work Order is issued pursuant to the Master Clinical Studies Agreement,
dated as of ______________ between IVIVI Technologies, Inc., ("Sponsor") and The
Cleveland Clinic Foundation (the "Agreement").

Any capitalized terms not otherwise defined herein shall have the same meaning
ascribed to them in the Agreement.

PROTOCOL TITLE AND NUMBER:

Use of Pulsed Electromagnetic Fields For Ischemic Cardiomyopathy Therapy: A
Randomized, Double-Blind, Parallel, Placebo-Controlled, Prospective Trial
(EFFECT TRIAL) (the "Study").

A copy of the Protocol is attached hereto as Schedule 1 and incorporated herein
by this reference.

PRINCIPAL INVESTIGATORS) NAME: Micheal Shen, MD, MS, FACC ("Investigator(s)")

Correspondence to Investigator can be addressed to the following:

Cleveland Clinic Florida
2950 Cleveland Clinic Blvd.
Weston, FL 33331

Phone: 954-659-500
Facsimile: 954-659-5291
E-mail: chenm@cf.org

A copy of the Investigator's Certification is attached hereto as Schedule 2, and
is incorporated herein by this reference.

SPONSOR' CLINICAL LEADER:

Correspondence to Sponsor' Clinical Leader can be addressed to the following:

____________________________________________
____________________________________________
____________________________________________
____________________________________________

Phone:
       _____________________________________
Facsimile:
           _________________________________
E-mail:
       _____________________________________

                                       16

<PAGE>

STUDY SCHEDULE:

1.   Study Initiation and Completion.

          (a) All contractual and regulatory documentation must be completed,
     executed and received by Sponsor no later than _____________________

          (b) The Study shall be initiated no later than _____________
     ("Initiation Date") and shall be completed no later than. ("Completion
     Date").

2.   Enrollment.

          (a) It is anticipated that the Principal Investigator(s) may enroll 40
     patients into the Study (the "Site Maximum"). Patient enrollment shall be
     completed on or before _______________. Enrollment of each patient over the
     Site Maximum requires the agreement of Sponsor.

          (b) Notwithstanding whether the Site Maximum has been reached, the
     Investigator(s) agrees to immediately cease enrolling patients upon notice
     from Sponsor that Sponsor' target enrollment for the Study has been
     achieved.

STUDY BUDGET, PAYMENT RECIPIENT AND MAILING ADDRESS

(NOTE: Specific Payment terms may vary dependent upon the nature of the Study
and the work being performed under the Protocol.)

This Work Order is entered into and made effective as of ______________________.

ACCEPTED AND AGREED TO BY:

SPONSOR                                 THE CLEVELAND CLINIC FLORIDA

-------------------------------------   ----------------------------------------
Signature                               Signature

-------------------------------------   ----------------------------------------
Typed Name and Title                    Typed Name and Title

Date:                                   Date:
     --------------------------------        -----------------------------------

                                       17<PAGE>

                                                                   Exhibit 10.17

                             STOCK OPTION AGREEMENT

     This Stock Option Agreement (this "Agreement") is made as of the 16th day
of June 2006, by and between Ivivi Technologies, Inc., a New Jersey corporation
(the "Corporation"), and Steven M. Gluckstern (the "Optionee").

                                   WITNESSETH:

     WHEREAS, the Optionee has agreed to serve as the Chairman of the Board of
Directors of the Corporation (the "Board"), effective as of the date (the
"Effective Date") the Corporation's Registration Statement on Form SB-2
(Registration No. 333-122768) (the "Registration Statement") relating to the
initial public offering (the "IPO") of the Corporation's common stock, no par
value per share (the "Common Stock"), is declared effective by the Securities
and Exchange Commission;

     WHEREAS, the Corporation intends to effect a stock split of 1.625 shares
for each outstanding share of Common Stock simultaneously with the effectiveness
of the Registration Statement (the "Stock Split"); and

     WHEREAS, the Board has approved the grant to the Optionee of an option to
purchase up to 775,000 shares of the Common Stock (after giving effect to the
Stock Split), subject to the terms and conditions of this Agreement.

     NOW, THEREFORE, in consideration of the foregoing and the mutual agreements
herein contained, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound, agree as follows:

     1. Grant of Option. The Corporation hereby grants the Optionee an option
(the "Option") to purchase from the Corporation an aggregate of up to 775,000
shares of Common Stock (after giving effect to the Stock Split)(collectively,
the "Option Shares"), in the manner and subject to the terms and conditions
provided in this Agreement. The Option is a non-statutory stock option and is
not intended to qualify as an incentive stock option under Section 422 of the
Internal Revenue Code of 1986, as amended, and the regulations thereunder. For
the avoidance of doubt, the Option is not being issued under the Ivivi
Technologies, Inc. 2004 Amended and Restated Stock Option Plan.

     2. Exercise Price. The per share exercise price of the Option (the "Option
Price") shall be $5.11 (after giving effect to the Stock Split).

     3. Exercise of Option.

          (a) Subject to such further limitations as are provided in this
Agreement, the Option may be exercised during the Option Term (as defined below)
as follows:

               (i)  from and after the earlier to occur of the consummation of
                    the IPO (the "IPO Closing") and the consummation of a
                    Qualified Offering (as defined below), provided that in each
                    case the Optionee is then serving as Chairman of the Board
                    (the "Vesting Date"), until the first anniversary of the
                    Vesting Date, the Option may be exercised as to 258,334 of
                    the Option Shares;

<PAGE>

               (ii) from and after the first anniversary of the Vesting Date
                    until the second anniversary of the Vesting Date, the Option
                    may be exercised as to 516,667 of the Option Shares; and

               (iii) from and after the second anniversary of the Vesting Date,
                    the Option may be exercised as to all of the Option Shares;

provided, however, if at any time during the period from the Vesting Date until
the second anniversary of the Vesting Date (the "Vesting Period"):

               (i) the Optionee ceases to serve as Chairman of the Board due to
his death or Disability (as defined below) or due to a termination without Cause
(as defined below), the Option shall immediately become exercisable as to all of
the Option Shares; or

               (ii) there is a Change of Control (as defined below) and the
Optionee is then serving as the Chairman of the Board, the Option shall become
exercisable as to all of the Option Shares immediately prior to the consummation
of the Change of Control (the "Change of Control Vesting Date").

          (b) For purposes of this Agreement, the following terms shall have the
following meanings:

               (i) "Cause" means the Optionee's (i) conviction of, plea of
guilty or nolo contendre to, or confession of guilt of, a felony or criminal act
involving moral turpitude, (ii) commission of a fraudulent, illegal or dishonest
act in respect of the Corporation or any of its affiliates or subsidiaries,
(iii) willful misconduct or gross negligence that reasonably could be expected
to be injurious in the reasonable discretion of the Board to the business,
operations or reputation of the Corporation or any of its affiliates or
subsidiaries (monetarily or otherwise), (iv) material violation of the
Corporation's policies or procedures in effect from time to time, (v) continued
failure to perform the Optionee's duties as Chairman of the Board after a
written warning and a period of 20 days immediately thereafter to cure such
non-performance or (vi) resignation from his position as Chairman of the Board.

               (ii) "Change of Control" means:

                    (A) any "person" (as such term is used in Section 13(d) and
14(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"))
becomes the "beneficial owner"(as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Corporation representing more than
50% of the total voting power represented by the Corporation's then outstanding
voting securities; provided, however, the consummation of the IPO or a Qualified
Offering and/or the exercise or conversion, as the case may be, of any options,
warrants, convertible notes or other instruments issued by the Company as of the
IPO Closing shall not be deemed a Change of Control;

                    (B) the consummation of a merger or consolidation of the
Corporation with any other entity, other than a merger or consolidation which
would result in the voting securities of the Corporation outstanding immediately
prior thereto continuing to represent (either by remaining outstanding or by
being converted into voting securities of the surviving entity) at least 50% of
the total voting power represented by the voting securities of the Corporation
or such surviving entity outstanding immediately after such merger or
consolidation; or

                    (C) the consummation of the sale or disposition by the
Corporation of all or substantially all of the Corporation's assets.

                                        2

<PAGE>

               (iii) "Disability" means a mental or physical impairment of the
Optionee that is expected to result in death or that has lasted or is expected
to last for a period of at least 120 consecutive days in any 12-month period or
150 non-consecutive days in any 12-month period and that causes the Optionee to
be unable to perform his duties as Chairman of the Board, as determined in the
sole discretion of the other members of the Board.

               (iv) "Qualified Offering" means an offering of the Corporation's
securities, whether in a private or public offering, in which the Corporation
raises gross proceeds of at least $5,000,000.

     4. Termination of Option.

          (a) The term of the Option (the "Option Term") shall be for a period
of ten (10) years from the Vesting Date, subject to earlier termination as
hereinafter provided. To the extent not exercised prior to the expiration of the
Option Term, the Option shall automatically terminate and be canceled upon the
expiration of the Option Term. Except to the extent provided in paragraphs (b)
and (c) below, upon the cessation of the Optionee's service as Chairman of the
Board for any reason, the Option, whether or not exercisable to any extent and
to the extent not previously exercised, shall automatically terminate and be
canceled.

          (b) If after the Vesting Date the Optionee ceases to be Chairman of
the Board due to his death or Disability, the Option may thereafter be
immediately exercised by the legal representative of the estate or the legatee
of the Optionee under the will of the Optionee or the Optionee, as the case may
be, for a period of one year from the date of such cessation until the
expiration of the Option Term, whichever period is shorter. If after the Vesting
Date the Optionee ceases to be Chairman of the Board due to a termination
without Cause, the Option may thereafter be immediately exercised by the
Optionee from the date of such cessation until the expiration of the Option
Term.

          (c) If after the Vesting Date there is a Change of Control and the
Optionee is then serving as the Chairman of the Board, the Option may be
immediately exercised by the Optionee from and after the Change of Control
Vesting Date until a date following the Change of Control Vesting Date specified
by the Board (the "Change of Control Vesting Expiration Date").

     5. Non-Transferability. The Option shall not be transferable otherwise than
by will or the laws of descent and distribution, in which case the transferee
must agree as a condition precedent to such transfer to be bound by the terms
hereof to the same extent that the Optionee is so bound, and the Option may be
exercised, during the lifetime of the Optionee, only by the Optionee. In
furtherance but without limiting the generality of the foregoing, the Option may
not be assigned, transferred (except as provided above), pledged or hypothecated
in any way, nor shall it be assignable by operation of law or subject to
execution, attachment or similar process. Any attempted assignment, transfer,
pledge, hypothecation, or other disposition of the Option contrary to the
provisions hereof, and the levy of any execution, attachment, or similar process
upon the Option, shall be null and void and without effect.

     6. Restrictions on Disposition. The Optionee hereby acknowledges that none
of the Option Shares are registered under the Securities Act of 1933, as amended
(the "Securities Act"), and the Corporation shall not be required to so register
any of the Option Shares. The Option Shares acquired by the Optionee pursuant to
this Agreement shall be subject to the restrictions on sale, encumbrance and
other disposition provided by Federal or State law, including, without
limitation Rule 144 of the Securities Act. As a condition precedent to receiving
Option Shares upon the exercise of this Option, the Corporation may require that
the Optionee submit a letter to the Corporation stating that (i) the Optionee is
an "accredited investor," as such term is defined in Rule 501 of Regulation D
promulgated under the

                                        3

<PAGE>

Securities Act, and (ii) the Option Shares are being acquired for investment and
not with a view to the distribution thereof. The Corporation shall not be
obligated to sell or issue any shares of Common Stock pursuant to this Agreement
unless, on the date of sale and issuance thereof, the Option Shares are either
registered under the Securities Act, and all applicable state securities laws,
or are exempt from registration thereunder. All Option Shares issued to the
Optionee pursuant to this Agreement may bear a restrictive legend summarizing
any restrictions on transferability applicable thereto, including those imposed
by Federal and state securities laws.

     7. Not a Contract of Service. Nothing in this Option Agreement shall confer
upon the Optionee any right to serve, or continue to serve, as Chairman of the
Board or interfere in any way with the right of the Corporation to terminate the
services of the Optionee at any time.

     8. Method of Exercise. Subject to the terms and conditions of this
Agreement, the Option may be exercised, in whole or in part, by written notice,
together with payment in full of the Option Price for the shares of Common Stock
to be purchased, to the Chief Financial Officer of the Corporation at the
principal office of the Corporation. Such notice shall state the number of
shares of Common Stock for which the Option is exercised. The date of such
exercise shall be the date on which the Corporation receives such notice and
payment. The Option Price for any shares purchased upon the exercise of the
Option or any portion thereof shall be payable in cash or by check made payable
to the order of the Corporation. The Option may not be exercised for a fraction
of a share of Common Stock.

     9. Withholding Requirements. Upon exercise of the Option by the Optionee
and prior to the delivery of shares purchased pursuant to such exercise, the
Corporation shall have the right to require the Optionee to remit to the
Corporation cash in an amount sufficient to satisfy applicable Federal and state
tax withholding requirements. The Corporation shall inform the Optionee as to
whether it will require the Optionee to remit cash for withholding taxes in
accordance with the preceding sentence within two (2) business days after
receiving from the Optionee written notice that such Optionee intends to
exercise all or a portion of the Option in accordance with Section 8.

     10. No Rights as a Stockholder. Neither the Optionee nor the Optionee's
executor, administrator, heirs or legatees shall have any rights as a
stockholder or any claim to dividends with respect to any shares of Common Stock
until the proper exercise of the Option as required hereby, the payment of the
purchase price for the applicable number of shares of Common Stock and the
issuance by the Corporation of a stock certificate representing such shares of
Common Stock so purchased upon exercise.

     11. Adjustment in Case of Stock Splits, Stock Dividends, Etc.

          (a) The number of shares, class of stock of the Corporation and Option
Price covered by this Option shall be adjusted by the Board or a proper
committee thereof, whose good faith determination with respect thereto shall be
conclusive, to reflect any stock dividend, common stock split, share
combination, exchange of shares, merger, consolidation, recapitalization,
separation, reorganization, liquidation or extraordinary dividend payable in
stock of a corporation other than the Corporation, all for the purpose of
providing dilution protection for the Common Stock, such that the Optionee shall
be entitled to purchase the number of shares which the Optionee would have been
entitled to receive immediately following such event had this Option been
exercised in full immediately prior to such event.

          (b) The parties hereto hereby acknowledge and agree that the number of
shares of Common Stock and Option Price covered by the Option give effect to the
Stock Split, and if the Stock Split is not effected prior to the Vesting Date,
such number of shares of Common Stock and Option Price shall be adjusted in
accordance with Section 11(a) to reflect that the Stock Split was not effected,
such

                                        4

<PAGE>

that the Optionee shall be entitled to purchase the number of shares which the
Optionee would have been entitled to receive without giving effect to the Stock
Split.

     12. Corporation Authority. The existence of the Option herein granted shall
not affect in any way the right or power of the Corporation or its shareholders
to make or authorize any adjustments, recapitalizations, reorganizations or
other changes in the Corporation's capital structure or business, any merger or
consolidation of the Corporation, any issue of bonds, debentures, preferred or
prior preference stock ahead of or affecting the Common Stock or the rights
thereof, the dissolution or liquidation of the Corporation, or any sale or
transfer of all or any part of the Corporation's assets or business, or any
other corporate act or proceeding, whether of a similar character or otherwise.

     13. Reservation of Shares. The Corporation shall at all times during the
Option Term reserve and keep available such number of shares of Common Stock as
will be sufficient to satisfy the requirements of this Agreement.

     14. Termination. Notwithstanding anything contained herein to the contrary,
if the Vesting Date does not occur by June __, 2007, this Agreement shall
automatically terminate and the Option shall automatically terminate and be
canceled.

     15. Miscellaneous Provisions.

          (a) Additional Documents. The Optionee hereby agrees to execute and
deliver such further documents and instruments as may be necessary or as may
reasonably be requested in order to effectuate fully the purposes, terms and
conditions of this Agreement, whether before, at or after the exercise of the
Option.

          (b) Notices. All notices, demands, requests, or other communications
that may be or are required to be given, served, or sent by a party pursuant to
this Agreement shall be in writing and shall be (i) personally delivered, (ii)
mailed by first-class, registered or certified mail, return receipt requested,
postage prepaid or (iii) sent by overnight delivery carrier, addressed as
follows:

               If to the Corporation:   Ivivi Technologies, Inc.
                                        224-S Pegasus Avenue
                                        Northvale, NJ 07647
                                        Attention: Chief Financial Officer

               If to the Optionee:      Steven M. Gluckstern
                                        c/o The Ajax Group of Companies
                                        44 Laight St. #1A
                                        New York, NY 10013

Each party may designate by notice in writing, in the manner described above, a
new address to which any notice, demand, request, or communication required or
permitted by this Agreement may be sent. Any notice, demand, request, or
communication that shall be delivered, mailed or transmitted in the manner
described above shall be deemed given, served, sent or received for all purposes
when it is delivered to the addressee. An affidavit of personal delivery, the
return receipt, or the delivery receipt shall be deemed conclusive, but not
exclusive, evidence of such delivery or when delivery is refused by the
addressee upon presentation.

          (c) Severability. The invalidity of any one or more provisions hereof
or of any other agreement or instrument given pursuant to or in connection with
this Agreement shall not affect the

                                        5

<PAGE>

remaining portions of this Agreement or any such other agreement or instrument
or any part thereof; and if one or more of the provisions contained herein or
therein should be invalid, or should operate to render this Agreement or any
such other agreement or instrument invalid, this Agreement and such other
agreements and instruments shall be construed as if such invalid provisions had
not been inserted.

          (d) Survival. Subject to the immediately preceding sentence, it is the
express intention and agreement of the parties hereof that all covenants and
agreements made in this Agreement shall survive the execution and delivery of
this Agreement and the exercise (if any) of the Option.

          (e) Waivers. Neither the waiver by a party of a breach of or a default
under any of the provisions of this Agreement, nor the failure of a party, on
one or more occasions, to enforce any of the provisions of this Agreement or to
exercise any right, remedy, or privilege hereunder shall thereafter be construed
as a waiver of any subsequent breach or default of a similar nature, or as a
waiver of any such provisions, rights, remedies, or privileges hereunder.

          (f) Binding Effect. Subject to any provisions hereof restricting
transfer, encumbrance and assignment, this Agreement shall be binding upon and
shall inure to the benefit of the parties hereto and their respective heirs,
personal representatives, successors, and assigns.

          (g) Limitation on the Benefit of this Agreement. It is the explicit
intention of the parties hereto that no person or entity other than the parties
hereof is or shall be entitled to bring any action to enforce any provisions of
this Agreement against any parties hereto, and that the covenants, undertakings,
and agreements set forth in the Agreement shall be solely for the benefit of,
and shall be enforceable only by, the parties hereto and their respective heirs,
personal representatives, successors and permitted assigns as permitted
hereunder.

          (h) Entire Agreement. This Agreement contains the entire agreement
among the parties with respect to subject matter hereof, and supersedes all
prior oral or written agreements, commitments, or understandings with respect to
the matters provided for herein and therein.

          (i) Headings. Article, section and subsection headings contained in
this Agreement are inserted for convenience of reference only, shall not be
deemed to be part of this Agreement for any purpose, and shall not in any way
define or affect the meaning, construction or scope of any of the provisions
hereof.

          (j) Governing Law. This Agreement shall be construed, and legal
relations between the parties hereto shall be determined, in accordance with the
laws of the State of New Jersey applicable to contracts solely executed and
wholly to be performed within the State of New Jersey without giving effect to
the principles of conflicts of laws.

          (k) Counsel. THE OPTIONEE REPRESENTS THAT HE AND/OR HIS OTHER
PROFESSIONAL ADVISORS HAVE HAD THE OPPORTUNITY TO REVIEW THIS AGREEMENT.

                  [Remainder of Page Intentionally Left Blank]

                                        6

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date first written above.

                                        IVIVI TECHNOLOGIES, INC.

                                        By: /s/ David Saloff
                                            ------------------------------------
                                        Name: David Saloff
                                        Title: President and Chief Executive
                                               Officer

                                        OPTIONEE

                                        /s/ Steven M. Gluckstern
                                        ----------------------------------------
                                        Name: Steven M. Gluckstern

                                        7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}]]